Fiche société
State University of New York at Buffalo
Traitements, essais et publications liés.
Traitements18programmes
Essais10liés
Publications16liées
SourceDBlocale
Traitements
18| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Acetaminophen 500Mg TabIn this pilot study, the investigators aim to compare two short-term pain relief methods administered over the course of 6 days in the setting of acute musculoskeletal (MSK) pain: 1. Methylprednisolone((Medrol)dose pack- standard taper per dose pack instructions 2. Standard of Care (SOC) which includes a combination of Acetaminophen (Tylenol)+Ibuprofen (Motrin) The investigators are interested in studying pain relief regimens for acute injury of any body part among an adult orthopaedic urgent care population. | Myopathies | Phase 4 | Traitement symptomatique | United States | À vérifier |
| Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab. | SEP | À vérifier | À vérifier | United States | À vérifier |
| Ibuprofen 200Mg Oral TabletIn this pilot study, the investigators aim to compare two short-term pain relief methods administered over the course of 6 days in the setting of acute musculoskeletal (MSK) pain: 1. Methylprednisolone((Medrol)dose pack- standard taper per dose pack instructions 2. Standard of Care (SOC) which includes a combination of Acetaminophen (Tylenol)+Ibuprofen (Motrin) The investigators are interested in studying pain relief regimens for acute injury of any body part among an adult orthopaedic urgent care population. | Myopathies | Phase 4 | Traitement symptomatique | United States | À vérifier |
| Lithium for Parkinson's: an Extension TrialThis study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials. | Parkinson | Phase 1/2 | À vérifier | United States | À vérifier |
| MayzentTo assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain. | SEP | Phase 2/3 | United States | À vérifier | |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | Cancer, Épilepsie, Hypertension, Myopathies, Parkinson, Sclérose latérale amyotrophique, SEP | Phase 2 | À vérifier | United States | À vérifier |
| Methylprednisolone 4Mg TabIn this pilot study, the investigators aim to compare two short-term pain relief methods administered over the course of 6 days in the setting of acute musculoskeletal (MSK) pain: 1. Methylprednisolone((Medrol)dose pack- standard taper per dose pack instructions 2. Standard of Care (SOC) which includes a combination of Acetaminophen (Tylenol)+Ibuprofen (Motrin) The investigators are interested in studying pain relief regimens for acute injury of any body part among an adult orthopaedic urgent care population. | Myopathies | Phase 4 | Traitement symptomatique | United States | À vérifier |
| ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSThe goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process. | SEP | À vérifier | Immunomodulation | United States | À vérifier |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSThe goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process. | SEP | À vérifier | Immunomodulation | United States | À vérifier |
| Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab. | SEP | À vérifier | À vérifier | United States | À vérifier |
| Lithium for Parkinson's: an Extension TrialThis study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials. | Parkinson | Phase 1/2 | À vérifier | United States | À vérifier |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | Myopathies | Non applicable | À vérifier | Belgium | À vérifier |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | Sclérose latérale amyotrophique | Phase 2 | À vérifier | United States | À vérifier |
| MayzentTo assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain. | SEP | Phase 2/3 | United States | À vérifier | |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | Hypertension | Non applicable | À vérifier | Nigeria | À vérifier |
| Methylprednisolone 4Mg TabIn this pilot study, the investigators aim to compare two short-term pain relief methods administered over the course of 6 days in the setting of acute musculoskeletal (MSK) pain: 1. Methylprednisolone((Medrol)dose pack- standard taper per dose pack instructions 2. Standard of Care (SOC) which includes a combination of Acetaminophen (Tylenol)+Ibuprofen (Motrin) The investigators are interested in studying pain relief regimens for acute injury of any body part among an adult orthopaedic urgent care population. | Myopathies | Phase 4 | Traitement symptomatique | United States | À vérifier |
| MetforminThe goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin | SEP | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Metformin | SEP | Phase 2 | NCT06463743 | Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) | RECRUITING |
| Methylprednisolone 4Mg Tab | Myopathies | Phase 4 | NCT07393503 | MOTION — Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries | ENROLLING_BY_INVITATION |
| Metformin | Hypertension | Non applicable | NCT07589387 | HTN2 — Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 | RECRUITING |
| Mayzent | SEP | Phase 2/3 | NCT04925557 | Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis | TERMINATED |
| Metformin | Sclérose latérale amyotrophique | Phase 2 | NCT04220021 | Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | ACTIVE_NOT_RECRUITING |
| Metformin | Myopathies | Non applicable | NCT00720161 | Metformin in Children With Motor Deficit | COMPLETED |
| Lithium for Parkinson's: an Extension Trial | Parkinson | Phase 1/2 | NCT06592014 | Lithium for Parkinson's: an Extension Trial | ENROLLING_BY_INVITATION |
| Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) | SEP | À vérifier | NCT05974839 | Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) | COMPLETED |
| ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS | SEP | À vérifier | NCT05974852 | ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS | COMPLETED |
| Metformin | Cancer | Phase 1 | NCT06044025 | A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy | RECRUITING |
Publications
16| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Metformin | Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial. | The lancet. Healthy longevity | ||
| Metformin | Adjunctive metformin for obesity and frailty in older people-puncturing inflated expectations? | The lancet. Healthy longevity | ||
| Metformin | Metformin Attenuates Sepsis-Induced Cardiomyopathy via Inhibition of Reverse Electron Transfer at Mitochondrial Complex I. | Biology | ||
| Metformin | Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. | Diabetes, obesity & metabolism | ||
| Metformin | SIRT1 in brain aging: molecular mechanisms and therapeutic potential of pharmacological and natural modulators. | Biogerontology | ||
| Metformin | Metformin enhances hippocampal excitatory synaptic transmission and preserves synaptic plasticity under amyloid-β oligomer-induced dysfunction. | Neuropharmacology | ||
| Metformin | Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network. | European journal of haematology | ||
| Metformin | Case Report: Early-onset euglycemic diabetic ketoacidosis following henagliflozin initiation in a treatment-naive patient. | Frontiers in endocrinology | ||
| Metformin | Beyond intraocular pressure: vascular and metabolic modifiers of optic nerve vulnerability in glaucoma. | International ophthalmology | ||
| Metformin | High Volume Hemofiltration : what are the last indications in 2026 - a narrative review. | Blood purification | ||
| Metformin | BAIBA attenuates pulmonary fibrosis by modulating the iron/ROS-mitochondrion-apoptosis cascade. | Free radical biology & medicine | ||
| Metformin | Evaluation of insulin, leptin, ghrelin, and adiponectin levels in type 2 diabetic patients receiving combined metformin-sulfonylurea therapy. | Biomeditsinskaia khimiia | ||
| Metformin | The efficacy of intermittent metformin plus lifestyle intervention for diabetes prevention in women with prediabetes and prior gestational diabetes: a randomized clinical, non-inferiority trial. | BMC medicine | ||
| Metformin | S2P-modified PLGA bifunctional nanodrug: inhibiting vascular senescence and foam cell formation for atherosclerosis treatment. | Journal of nanobiotechnology | ||
| Metformin | Medicolegal autopsy reconstruction of a medication-related adverse event trajectory in a psychiatric inpatient with diabetes: a case report. | Journal of medical case reports | ||
| Metformin | Corrigendum to "Metformin prevents mandibular bone loss in a mouse model of accelerated aging by correcting dysregulated AMPK-mTOR signaling and osteoclast differentiation" [J Orthop Transl 46 (2024) 129-142]. | Journal of orthopaedic translation |